Results 41 to 50 of about 17,901 (223)

Balloon-expandable stent graft for coral reef aorta

Journal of Vascular Surgery Cases and Innovative Techniques, 2020
Coral reef aorta (CRA) is a rare aortic occlusive disease with calcified intraluminal lesions. We report the case of a patient with CRA who underwent endovascular treatment (EVT). A 78-year-old woman presented with intermittent claudication.
Ryutaro Isoda, MD, Ichiro Morita, MD, PhD, Masayuki Mano, MD, PhD, Atsuhisa Ishida, MD, PhD   +3 more
doaj   +1 more source

Intermittent Claudication in the Aged

Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics, 1974
昭和44年1月より昭47年12月までに当所に受診した40歳以上の患者より, 糖負荷試験, 鼠径部動脈雑音などの検索をしえた男398例, 女232例について間歇性跛行(「跛行」) を検討した.「跛行」は男27例 (6.8%), 女2例 (0.9%) に認められ, 男では40歳代1.0%, 50歳代2.7%, 60歳代9.2%, 70歳以上23.3%, と加齢とともに増加した. 60歳以上の男184例について検討すると, 収縮期血圧, 血清コレステロール, 糖同化機能には「跛行」群と対照群との間に差はなく, 拡張期血圧は「跛行」群で低くかった. 喫煙者は「跛行」群87.0%, 対照群62.7%で「跛行」群に有意に多かった. 腹部大動脈石灰化も「跛行」群で82.6%に認められ, 対照群41.6%に比し多く,
M, Kuramochi, A, Seki, J, Fujii
openaire   +3 more sources

Naftidrofuryl for intermittent claudication [PDF]

Cochrane Database of Systematic Reviews, 2008
Lifestyle changes and cardiovascular prevention measures are a primary treatment for intermittent claudication (IC). Symptomatic treatment with vasoactive agents (Anatomic Therapeutic Chemical Classification (ATC) for medicines from the World Health Organisation class CO4A) is controversial.To evaluate evidence on the efficacy and safety of oral ...
T L M, De Backer, R, Vander Stichele, P, Lehert, L, Van Bortel   +3 more
openaire   +3 more sources

A Rare Case of Intermittent Claudication Associated with Impaired Arterial Vasodilation

Case Reports in Vascular Medicine, 2017
Exercise-related intermittent claudication is marked by reduced blood flow to extremities caused by either stenosis or impaired vascular function. Although intermittent claudication is common in the elderly, it rarely occurs in the young and middle-aged ...
J. J. Posthuma, K. D. Reesink, M. Schütten, C. Ghossein, M. E. Spaanderman, H. ten Cate, G. Schep   +6 more
doaj   +1 more source

Protocol for the Stimulating β3-Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial: a double-blinded, randomised, placebo-controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral arterial disease

BMJ Open, 2021
Introduction There is currently only one approved medication effective at improving walking distance in people with intermittent claudication. Preclinical data suggest that the β3-adrenergic receptor agonist (mirabegron) could be repurposed to treat ...
Clara Chow, Anthony C Keech, Laurent Billot, Sanjay Patel, Kristen J Bubb, Stuart M Grieve, Gemma A Figtree, Jonathan Golledge, Jason A Harmer, Meghan Finemore, Sarah Joy Aitken, Zara S Ali, Rebecca Mister, Michael P Gray, Naomi Hamburg, Vikram Puttaswamy   +15 more
doaj   +1 more source

Neuropsychiatric symptoms in patients with aortic aneurysms. [PDF]

PLoS ONE, 2011
BACKGROUND: Emerging evidence suggests that vascular disease confers vulnerability to a late-onset of depressive illness and the impairment of specific cognitive functions, most notably in the domains of memory storage and retrieval.
Bernhard T Baune, Steven J Unwin, Frances Quirk, Jonathan Golledge   +3 more
doaj   +1 more source

The effect of sequential intermittent pneumatic compression of foot and calf on popliteal artery mean systolic blood flow in patients with intermittent claudication

Asian Journal of Surgery, 2012
Objective: To determine the effect of intermittent pneumatic foot and calf compression on popliteal artery mean systolic blood flow in patients with intermittent claudication. The secondary objective was to determine the change in blood flow with posture.
Daphne Anthonysamy, Zainal Ariffin Azizi, Hafizan Mohd Tajri   +2 more
doaj   +1 more source

A systematic review of exercise testing in patients with intermittent claudication: A focus on test standardisation and reporting quality in randomised controlled trials of exercise interventions.

PLoS ONE, 2021
A systematic review was conducted to identify the range of terminology used in studies to describe maximum walking distance and the exercise testing protocols, and testing modalities used to measure it in patients with intermittent claudication.
Stefan T Birkett, Amy E Harwood, Edward Caldow, Saïd Ibeggazene, Lee Ingle, Sean Pymer   +5 more
doaj   +1 more source

Efficacy and Safety of Adjunctive Cilostazol to Clopidogrel‐Treated Diabetic Patients With Symptomatic Lower Extremity Artery Disease in the Prevention of Ischemic Vascular Events

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Type 2 diabetes mellitus is a risk factor for lower extremity arterial disease. Cilostazol expresses antiplatelet, anti‐inflammatory, and vasodilator actions and improves the claudication intermittent symptoms. We investigated the efficacy and
Kallirroi Kalantzi, Nikolaos Tentolouris, Andreas J. Melidonis, Styliani Papadaki, Michail Peroulis, Konstantinos A. Amantos, George Andreopoulos, George I. Bellos, Dimitrios Boutel, Magdalini Bristianou, Dimitrios Chrisis, Nikolaos A. Dimitsikoglou, John Doupis, Chrysoula Georgopoulou, Stergios A. Gkintikas, Styliani Iraklianou, Κonstantinos Kanellas, Kalliopi Kotsa, Theocharis Koufakis, Maria Kouroglou, Anastasios G. Koutsovasilis, Leonidas Lanaras, Eirini Liouri, Charalampos Lixouriotis, Akrivi Lykoudi, Efthymia Mandalaki, Evanthia Papageorgiou, Nikolaos Papanas, Spyridon Rigas, Maria I. Stamatelatou, Ioannis Triantafyllidis, Aikaterini Trikkalinou, Aikaterini N. Tsouka, Ourania Zacharopoulou, Christos Zoupas, Ioannis Tsolakis, Alexandros D. Tselepis   +36 more
doaj   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source